ARTICLE | Company News
Boehringer, Epizyme to develop small molecules against epigenetic cancer targets
November 16, 2018 7:27 PM UTC
Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with Epizyme Inc. (NASDAQ:EPZM) to develop small molecule inhibitors of two undisclosed epigenetic cancer targets in the helicase and histone acetyltransferase (HAT) families.
The companies plan to focus on lung cancer and other solid tumors with defined mutations that lack precision medicine treatments...